On March 9, 2026, Relmada Therapeutics, Inc. announced a private placement to raise approximately $160 million by selling 29.5 million shares of common stock at $4.75 each, along with warrants. This funding will support working capital and R&D efforts for their product candidates, particularly for NDV-01 in bladder cancer treatment.